Dacihal Injection 0.5mg

Active Ingredient: Dactinomycin

Introduction

Dacihal 0. is a prescription medication that contains the active ingredient Dactinomycin. It is available in the form of an injectable solution. Dactinomycin is also known by its generic name, Actinomycin D.

Uses

Dacihal 0. is primarily used in the treatment of certain types of cancer. It is commonly prescribed for the treatment of Wilms tumor (a kidney cancer that primarily affects children), rhabdomyosarcoma (a soft tissue cancer), and gestational trophoblastic neoplasia (a group of rare tumors that form in the uterus during pregnancy).

Dosage and Administration

Dacihal 0. should only be administered under the supervision of a healthcare professional who is experienced in the use of anticancer medications. The dosage and frequency of administration may vary depending on the specific cancer being treated and the patient’s individual factors. Follow the instructions provided by your healthcare provider.

Mechanism of Action

Dactinomycin works by interfering with the growth and reproduction of cancer cells. It belongs to a class of medications known as antineoplastic antibiotics. Dactinomycin binds to the DNA in cancer cells, preventing them from dividing and multiplying. This helps to slow down or stop the growth of the tumor.

Side Effects

Common side effects may include nausea, vomiting, loss of appetite, fatigue, and hair loss. Discuss any side effects with your healthcare provider. In rare cases, Dacihal 0. may cause serious side effects such as bone marrow suppression, which can lead to a decreased production of blood cells. If you experience any unusual bleeding, bruising, or signs of infection, seek medical attention immediately.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription drugs, over-the-counter medications, and any herbal or dietary supplements. Dacihal 0. may interact with certain medications, such as vaccines, live vaccines, and other anticancer drugs. These interactions can affect the effectiveness of the medication or increase the risk of side effects. Your healthcare provider will monitor your treatment closely and adjust your medication as needed.

Precautions

Before starting treatment with Dacihal 0., inform your healthcare provider about any medical conditions you have, especially if you have a history of liver or kidney problems. Dacihal 0. may not be suitable for individuals with certain conditions or who are taking specific medications. Discuss your medical history and current medications with your healthcare provider to ensure the safe and effective use of this medication.

Storage

Dacihal 0. should be stored at controlled room temperature, between 20°C and 25°C (68°F and 77°F). It should be kept in its original packaging to protect it from light. Do not freeze the medication. Keep it out of the reach of children and pets.

Patient Tips

• attend all scheduled appointments with your healthcare provider for monitoring and follow-up.
• Dacihal 0. may cause temporary hair loss. Discuss options for managing hair loss with your healthcare provider.
• Avoid contact with individuals who have recently received live vaccines while you are receiving treatment with Dacihal 0..
• Report any signs of infection, unusual bleeding, or bruising to your healthcare provider.
• Follow your healthcare provider’s instructions regarding any dietary restrictions or specific precautions to take while receiving Dacihal 0..

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Dactinomycin (Drugs.com) [Accessed 27 Jun. 2024] (online) Available at:
• dactinomycin solution, reconstituted (recon soln) (RX) [Accessed 13 Jun. 2024] (online) Available at:
• Dactinomycin (MedlinePlus) [Accessed 19 Jun. 2024] (online) Available at:
• [No authors listed] Dactinomycin. Med Lett Drugs Ther. 1965 May 21;7(11):41-2. [Accessed 21 Jun. 2024] Available at: